MTN-028 Laboratory Related CRFs. Pharmacokinetics Specimens (PKS-1) - Enrollment, Day 28 Pharmacokinetics Specimens (PKD-1) - Days 1, 2, 3, 7, 14, 21,

Slides:



Advertisements
Similar presentations
1 MTN-003 Training Follow-up Visit Scheduling and Visit Coding SSP Sections and
Advertisements

Overview of Follow-up Visit Types and Visit Scheduling Training Binder Tab: Follow-up Visits.
ASPIRE Off-Site Visits. Rationale Why make an allowance for off-site visits in the protocol? Adherence & Retention Off-site visits Improving Clinic Flow.
HIV Counseling &Testing. Page 346 HIV and Risk Reduction (RR) Counseling Required at all scheduled visits Includes HIV Pre- and Post-test counseling.
1 MTN-003 Study Specific Training Randomization Overview.
ASPIRE TRAINING RANDOMIZATION & INITIAL DISPENSING Cindy Jacobson, PharmD (MTN) Jen Berthiaume/Missy Cianciola (SCHARP)
Health Assessment Abnormal Cases. Objective Review Health Assessment Status transitions for abnormal cases Record HA (Health Assessment) Results for an.
Reportable AEs – Report on AE Log CRF
CTR Form B: Testing Information. Overview: Form B collects information about the testing and counseling services provided to a client. It is intended.
G ENITAL B LEEDING ASPIRE SSP Section Updates 31 January 2014.
EDRN’s Validation Study Information Management System Developed for EDRN by the DMCC Cancer Biomarkers Group Division of Cancer Prevention Jet Propulsion.
Adverse Events for VOICE Additional Examples. Is it an Adverse Event? Suppose a participant is found to have a grade 3 ALT after her Month 1 visit. Is.
1 MTN-003 Training Specimen Labeling and Preparation for Entry into LDMS.
Contraception/Pregnancies MTN 020. Why do we care? Participants must come off product during pregnancy and breastfeeding – Studies of dapivirine in pregnant.
Baseline Medical and Menstrual History The ins, outs, ups, and downs of collecting a relevant and complete baseline medical/menstrual history MTN 020 Training.
Genital Bleeding MTN 020 Training. Background  Genital Bleeding is common Includes menses Includes intermenstrual bleeding (IMB)  Determining whether.
ASPIRE (MTN-020) Laboratory Training Edward Livant MT (ASCP), MPH University of Pittsburgh Medical Center Yaw Agyei MT (ASCP) Johns Hopkins University.
MTN-027 Screening Visit Procedures. SSP Manual References Protocol Section 7.2 and Table 10 (Screening) Section 4: Study Procedures Section 5: Informed.
California Department of Public Health Office of AIDS Guide for Health Department Surveillance Staff Collecting Data on the new Testing and Treatment History.
MTN-028 Study Overview Phase 1 Pharmacokinetic Trial of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048.
ASPIRE TRAINING Study Product Considerations & Accountability for Non-Pharmacy Staff.
MTN-027 Clinical Considerations. Overview of Discussion Topics Baseline Medical/Medication History Follow-up Medical/Medication History Physical/Pelvic.
MTN-028 Enrollment Visit Procedures Phase 1 Pharmacokinetic Trial of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176)
Billing Agent. Pre-Application Checklist Introduction to IMPACT and Key Terms Application Process Starting an Application The Business Process Wizard.
AE/SAE/EAE Identification and Reporting AE/SAE/EAE Identification and Reporting.
ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Product Use Management MTN 020 Training. Objectives- study product tab  Identify the conditions that would require a product hold or discontinuation.
MTN-028 Laboratory Training May Beamer, Lorna Rabe MTN Laboratory Center Magee-Womens Research Institute Pittsburgh, PA.
Overview of Enrollment Procedures. Training Materials for this session  All materials for this session can be found under the Enrollment tab of your.
MTN-027 Laboratory Related CRFs. Pharmacokinetics Specimens (PKS-1) - Enrollment, Day 28 Pharmacokinetics Specimens (PKD-1) - Days 1, 2, 3, 7, 14, 21,
SMART Study Closeout Washington ICC Meeting 03 June 2007.
AE/SAE/EAE Identification and Reporting AE/SAE/EAE Identification and Reporting.
Follow-up Visit Procedures MTN-028 Study Specific Training.
Informed Consent Process: Key Considerations. Introduction  Informed consent is a requirement of ethical clinical research  Section 4.8 of the International.
Fifth Annual President’s Emergency Plan for AIDS Relief Track 1.0 ART Program Meeting September , 2007 Thomas J. Spira, M.D. International Laboratory.
MTN-027 Clinical Management CRFs. CRFs for Clinical Management Physical Exam Pelvic Exam Diagrams Pelvic Exam Pelvic Exam Ring Assessment Clinical Product.
Investigator’s Meeting
Newborn Screening Translational Research Network Virtual Repository of Dried Blood Spots Supplemental Slides February 16, 2012 Call in Number: (470)
**INSERT YOUR TITLE HERE**
Protocol Deviations. MTN protocol deviation policy  MTN has recently revised their policy on PDs- this policy will be made available on the MTN website.
Thanks for giving me an opportunity to share with you our process for controlling media and other supplies. Disclaimer: We are not yet accredited to ISO.
Laboratory diagnoses of infections agents. DIFFERENT TYPES OF AND APPROACHES TO CLINICAL SAMPLE COLLECTION.
TIPS FOR COMPLETING CRF’S October Antimicrobial Report Form 7  In iDataFax use the drop-down list to record the Antimicrobial Code. This will.
Follow-up Case Report Forms SCHARP. Follow-up Visit CRFs Monthly Visits Date of Visit Follow-up Visit Summary Ring Adherence (Y/N) prompt Laboratory Results.
Protocol Requirements for Product Holds/Discontinuations MTN-025.
1 HOPE Product Use Management: HIV Infection no rapid test(s) positive CONTINUE product. HOLD product pending confirmatory testing. PERMANENTLY DISCONTINUE.
Overview of Key Clinical Considerations MTN 025 Training.
HOPE (MTN-025) Laboratory Training Edward Livant MT (ASCP), MPH University of Pittsburgh Medical Center.
Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute.
Overview of Screening Visit Procedures, PTID Assignment, Screening & Enrolment Logs, and Screen Failures Objectives: Review screening visit procedures.
Planning for HOPE PUEVs and Study Exit Visits
IMPAACT 2010 Screening Visits
Maternal Schedule of Evaluation
Infant clinical considerations
30 April 2015 Updated 29 December 2015
MTN-036 Study of Extended Duration Dapivirine Vaginal Ring for HIV Prevention How do I know if I’m Eligible to join? Women who join the study must.
MTN-025 Data Communiqué #1 CRF Updates.
HOPE STUDY PRODUCT TRAINING PHASE 2
IMPAACT 2010 Screening Visits
MTN-037 Training Julie Ngo SCHARP April 12, 2018.
MTN-037 Screening and Enrollment
Follow-up Visit Considerations
MTN-020 Common QCs and Form Completion Questions
MTN 037 Laboratory Training
PRE CRF at Enrollment Visit
Protocol Requirements for Product Holds/ Discontinuations
MTN-037 Protocol Overview
HOPE STUDY PRODUCT TRAINING
ASPIRE Common QCs - PUEV and SEV
TRACE INITIATIVE: Data Collection Tools and Forms
Presentation transcript:

MTN-028 Laboratory Related CRFs

Pharmacokinetics Specimens (PKS-1) - Enrollment, Day 28 Pharmacokinetics Specimens (PKD-1) - Days 1, 2, 3, 7, 14, 21, 29, 30, 31, 35) Specimen Storage HIV Results HIV Confirmatory Results Ring Collection and Insertion Safety Laboratory Results STI Test Results Laboratory Related CRFs

Record start and stop date for last menstrual period during the last 30 days Select if blood and vaginal fluid samples for PK were stored, not stored or not collected – If not stored, specify why There is no item 2 on the Enrollment form because there is no 0-hour blood draw at enrollment Collection times are documented on the LDMS tracking form Pharmacokinetics – Enrollment CRF

Record the start and stop date for occurrence of last vaginal bleeding in the last 30 days Select if the single- time blood and vaginal fluid for PK were stored, not stored or not collected – If not stored, specify why Pharmacokinetics – Days 1-21, CRF

Similar to the Enrollment PK form, except the Day 28 form includes the 0-hour blood draw and last date of vaginal bleeding question If silver nitrate/monsels solution is used to stop bleeding during the collection of cervical biopsies, this should be noted in the comments section to better inform PK analyses Pharmacokinetics – Day 28 CRF

Specimen Storage form: Completed at Enrollment, Day 3, Day 28 and Day 35 Documentation for: – Vaginal smear for gram stain – Collection of the used vaginal ring and collection time Specimen Storage (SS-1) CRF

Safety Laboratory Results CRF: Complete at Enrollment and at Day 28 and 35 Visits Page 1 documents Hemogram and Differential If Severity is Grade 1 or higher, it should be entered, if below Grade 1 leave the “Severity Grade” box blank Record any AE Log Page #’s associated with the lab result Safety Laboratory Results (SLR-1) CRF

Safety Laboratory Results CRF page 2: Documentation for chemistries and Dipstick UA results Grade the severity of the urine glucose value according to the “Proteinuria, random collection” row of the DAIDS Table V1.0 Safety Laboratory Results (SLR-2) CRF

Ring Collection and Insertion (RCI-1) CRF Required on Day 28 to document ring collection Complete as needed if an additional ring is dispensed or a ring is returned during the study- not expected

Ring Collection and Insertion (RCI-1) CRF Item 1a: If the ring was removed prior to Day 28, indicate the date that the ring was last in place Item 4: If a ring was inserted at this visit, indicate the time that the ring was inserted in item 4a.

HIV Results CRF Complete this form at Day 35/Final Clinic Visit and if indicated during follow-up If test is positive or indeterminate, complete the HIV Confirmatory Results CRF and document product hold on PH-1

HIV Confirmatory Results CRF Complete this form for each visit where the participant has a positive or indeterminate EIA test In Item 2, mark ‘pending’ if the participant’s final HIV status is not clearly known and update once final status is determined

STI Results CRF Complete this form, if indicated, to document Vaginal Wet Prep, rapid Trich, GC/CT and syphilis testing during follow up If a test result(s) indicates that the participant has a new (or increased severity) laboratory- confirmed infection or diagnosis, this must be recorded as an adverse experience on an Adverse Experience (AE) Log

STI Results CRF If vaginal wet prep was performed but not all assays were completed, mark “Not done/Not collected” for each uncompleted wet prep assay